PKUMDL WQ 2201 structure
|
Common Name | PKUMDL WQ 2201 | ||
---|---|---|---|---|
CAS Number | 592474-91-4 | Molecular Weight | 351.808 | |
Density | 1.4±0.1 g/cm3 | Boiling Point | 523.5±60.0 °C at 760 mmHg | |
Molecular Formula | C15H14ClN3O3S | Melting Point | N/A | |
MSDS | N/A | Flash Point | 270.4±32.9 °C |
Use of PKUMDL WQ 2201PKUMDL-WQ-2201 is a PHGDH non-NAD+-competing allosteric inhibitor (IC50=35.7 μM). PKUMDL-WQ-2201 also inhibits PHGDH mutants with IC50s of 69 μM (T59A) and >300 μM (T56AK57A), respectively. PKUMDL-WQ-2201 inhibits de novo serine synthesis in cancer cells, and reduces tumor growth[1][2]. |
Name | PKUMDL-WQ-2201 |
---|---|
Synonym | More Synonyms |
Description | PKUMDL-WQ-2201 is a PHGDH non-NAD+-competing allosteric inhibitor (IC50=35.7 μM). PKUMDL-WQ-2201 also inhibits PHGDH mutants with IC50s of 69 μM (T59A) and >300 μM (T56AK57A), respectively. PKUMDL-WQ-2201 inhibits de novo serine synthesis in cancer cells, and reduces tumor growth[1][2]. |
---|---|
Related Catalog | |
Target |
IC50: 35.7 μM (PHGDH WT), 69 μM (PHGDH T59A), >300 μM (PHGDH T56AK57A)[1] |
In Vitro | PKUMDL-WQ-2201 (10 nM-100 μM; 3 d) 对 PHGDH 扩增的乳腺癌细胞系具有良好的选择性和抑制作用,EC50 值分别为 7.7 μM (MDA-MB-468) 和 10.8 μM (HCC70)[1]。 |
In Vivo | PKUMDL-WQ-2201 (5-20 mg/kg; 腹腔注射; 每天 1 次, 共 30 天) 与对照组小鼠相比,对 MDA-MB-468 异种移植有显著的抑制作用,但不影响肿瘤生长[1]。 |
References |
Density | 1.4±0.1 g/cm3 |
---|---|
Boiling Point | 523.5±60.0 °C at 760 mmHg |
Molecular Formula | C15H14ClN3O3S |
Molecular Weight | 351.808 |
Flash Point | 270.4±32.9 °C |
Exact Mass | 351.044434 |
LogP | 2.79 |
Vapour Pressure | 0.0±1.4 mmHg at 25°C |
Index of Refraction | 1.647 |
2-Chloro-4-(5-{[(ethylcarbamothioyl)hydrazono]methyl}-2-furyl)benzoic acid |
Benzoic acid, 2-chloro-4-[5-[[2-[(ethylamino)thioxomethyl]hydrazinylidene]methyl]-2-furanyl]- |
PKUMDL-WQ-2201 |
2-chloro-4-(5-{2-[(ethylamino)carbothioyl]carbohydrazonoyl}-2-furyl)benzoic acid |
2-Chloro-4-[5-[[2-[(ethylamino)thioxomethyl]hydrazinylidene]methyl]-2-furanyl]-benzoic acid |